Related Experiment Videos
Anthracycline resistance in breast cancer: clinical applications of current knowledge
1Division of Oncology University of Texas Health Sciences Center, San Antonio 78284, USA.
Abstract:
Anthracyclines are highly effective antineoplastic agents for the treatment of breast cancer. Nevertheless, essentially all breast cancer patients have tumours which are intrinsically resistant or which develop resistance during the course of therapy. Clinical trials provide indirect information on the nature of anthracycline resistance and work in the basic sciences has demonstrated molecular mechanisms which play a role. Initial clinical attempts to exploit and translate these mechanisms to predict, and interfere with, anthracycline resistance have met with mixed success, and have not yet led to accepted clinical applications.
Insights
Anthracyclines are vital for breast cancer treatment but resistance is common. Understanding molecular mechanisms of resistance is key to improving therapy effectiveness.
Area of Science:
- Oncology
- Pharmacology
Background:
- Anthracyclines are effective breast cancer treatments.
- Tumor resistance to anthracyclines is a significant clinical challenge.
- Both intrinsic and acquired resistance mechanisms exist.
Purpose of the Study:
- To review the molecular mechanisms of anthracycline resistance in breast cancer.
- To assess the clinical translation of understanding these resistance mechanisms.
- To identify challenges and opportunities for overcoming resistance.
Main Methods:
- Review of clinical trial data.
- Analysis of basic science research on molecular resistance pathways.
- Evaluation of translational studies.
Main Results:
- Molecular mechanisms of anthracycline resistance have been identified.
- Clinical trials provide indirect evidence of resistance factors.
- Translational efforts to predict or overcome resistance have yielded mixed results.
Conclusions:
- Despite advances in understanding, effective clinical strategies to combat anthracycline resistance are lacking.
- Further research is needed to bridge the gap between basic science discoveries and clinical applications.
- Developing predictive biomarkers and novel therapeutic interventions remains a priority.